AstraZeneca secures FDA and EU approvals for Klygefa: Can AZN hold recent gains?

AstraZeneca secures FDA and EU approvals for Klygefa: Can AZN hold recent gains?
AstraZeneca rises 0.54% to GBX14,058

AstraZeneca (AZN) stock is trading at GBX14,058 after a modest rise today. The price finished the session above its short-, medium-, and long-term moving averages, reflecting ongoing positive pressure across all major trend horizons.

AZN price prediction
24H -0.25%
GBX 13,406
48H -0.53%
GBX 13,369.19
7D -0.11%
GBX 13,425
1M 12.56%
GBX 15,128
3M 23.74%
GBX 16,630.27
6M 36.76%
GBX 18,379.92
12M 9.54%
GBX 14,721.55
Current price: GBX 13,440 136.00 1.02%
Closed 11/20
Daily range 13350.00 Arrow from to Icon 13538.00
Weekly range 13274.00 Arrow from to Icon 14222.00
Loading...

Highlights

  • AstraZeneca received regulatory approvals in the U.S. and Europe for Klygefa, expanding its immunology and rare disease portfolio.
  • The FDA also approved Imfinzi combined with enfortumab vedotin for bladder cancer and the company is reducing U.S. sales staff by 600 to boost efficiency.
  • Shares of AstraZeneca closed up 0.54% at GBX14,058 with technicals showing moderate bullish signals and a projected range of GBX13,913 to GBX14,244 in coming sessions.

Regulatory gains and restructuring drive revenue prospects and efficiency

AstraZeneca's recent receipt of regulatory approvals from both the U.S. FDA and the European Commission for Klygefa (gefurulimab) significantly enhances its potential to capture new prescription revenues in the immunology space, as reported by Sharecast. Access to the U.S. and European markets for this therapy broadens the company's competitive position and underpins expansion in rare disease treatments. In parallel, the U.S. FDA's approval of Imfinzi in combination with enfortumab vedotin offers new opportunities in bladder cancer treatment, according to Investing.com, while ongoing restructuring through the cut of 600 sales jobs in the U.S. reflects an effort to improve operational efficiency and reassign internal resources.

AstraZeneca asset chart
AstraZeneca price dynamics. Source: TradingView.

Bullish momentum supported by indicators as technical floor holds

AZN is trading above the H1 SMA-20 at GBX14,020, above the H1 SMA-50 at GBX13,991, and well above the D1 SMA-200 at GBX13,440. The Ichimoku Kijun level at GBX14,056 now acts as immediate technical support. Momentum indicators show MACD signaling Buy and ADX reading Neutral, suggesting moderate bullish sentiment without confirmed trend strength. RSI, Stoch RSI, and CCI remain in neutral zones, indicating neither overbought nor oversold conditions, and Bull/Bear Power continues to display a positive value intraday. The Awesome Oscillator further supports underlying bullish momentum.

Upside bias likely as price consolidates within volatility band

In the short term, AZN is expected to consolidate within a volatility band between GBX13,913 and GBX14,244. There is a 67% probability that the price will attempt a move higher, while the risk of a downside push stands at 33%. The baseline scenario anticipates trading within this corridor, with an upside breakout possible if positive momentum persists, and a more bearish outlook developing only if the price slides below immediate support at the Ichimoku Kijun.

Anton Kharitonov, analyst at Traders Union, notes that AstraZeneca's latest regulatory approvals provide new growth options in both immunology and cancer treatment, but cost-cutting steps signal ongoing internal pressures. He sees the stock holding above short-, medium- and long-term moving averages, including the H1 SMA-20 at GBX14,020, yet momentum indicators are mixed and do not confirm a strong trend. The analyst remains cautious, as consolidation between GBX13,913 and GBX14,244 is likely until a break in either direction. "Base case remains sideways — I would watch the Ichimoku Kijun at GBX14,056 for signs of a shift before making any tactical calls."

Earlier, analysts noted that AstraZeneca’s shares exhibited strong technical momentum and breakout potential, anchored by recent FDA approvals and strategic restructuring. The current analysis reinforces this outlook with sustained bullish momentum and expanded regulatory wins, while highlighting GBX14,056 as a key support level for traders monitoring short-term price action.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.